Preclinical Transplantation and Safety of HS/PCs Expanded from Human Umbilical Cord Blood
Chun-Juan Guo,Ying Gao,Di Hou,Dong-Yan Shi,Xiang-Min Tong,Dan Shen,Yong-Mei Xi,Jin-Fu Wang
DOI: https://doi.org/10.4252/wjsc.v3.i5.43
2011-01-01
World Journal of Stem Cells
Abstract:AIM: To expand hematopoietic/progenitor stem cells （HS/PCs） from umbilical cord blood （UCB） and prepare the HS/PC product, and analyze preclinical transplantation and safety of HS/PC product. METHODS: Human bone marrow-derived mesenchymal stem cells （MSCs） were used as feeder cells to expand HS/PCs from UCB in a serum-free culture system. The proliferation potential of HS/PCs was analyzed. The expanded HS/PCs were suspended in the L-15 medium to prepare the HS/PC product. The contamination of bacteria, fungi and mycoplasmas, the infection of exogenous virus, the concentration of bacterial endotoxin, and the SCF residual in HS/PC product were determined. Finally, cells from the HS/PC product with or without bone marrow-derived mesenchymal stem cells （BM-MSCs） were transplanted into the irradiated NOD/SCID mice to determine the in vivo engraftment potential. RESULTS: After co-culture for 10 d, the total nuclear cells （TNCs） increased 125-fold, and CD34 + cells increased 43-fold. The granulocyte-macrophage colonyforming cells （GM-CFCs） and erythroid colony-forming cells （E-CFCs） increased 3.3and 4.7-fold respectively. The expanded cells were collected and prepared as the expanded product of HS/PCs by re-suspending cells in L-15 medium. For preclinical safety, the HS/PC product was analysed for contamination by bacteria, fungi and mycoplasmas, the bacterial endotoxin concentration and the SCF content. The results showed that the HS/PC product contained no bacteria, fungi or mycoplasmas. The bacterial endotoxin concentration was less than the detection limit of 6 EU/mL, and residual SCF was 75 pg/mL. Based on clinical safety, the HS/PC product was qualified for clinical transplantation. Finally, the HS/PC product was transplanted the irradiated mice where it resulted in rapid engraftment of hematopoietic cells. CONCLUSION: HSPC product prepared from UCB in the serum-free culture system with hMSCs as feeder cells should be clinically safe and effective for clinical transplantation.